Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C89H125N23O25S3 |
| Molecular Weight | 2013.2856 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 20 / 20 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H]3NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@@H]5CCCN5C(=O)CNC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@@H]7CNCCCC[C@H](NC(=O)[C@@H]8NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CSC[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CS[C@H]8C)C(=O)N[C@@H](CS[C@H]3C)C(=O)N7)NC1=O)[C@@H](O)C(O)=O)C(O)=O
InChI
InChIKey=SFWLDKQAUHFCBS-AOEYGKNYSA-N
InChI=1S/C89H125N23O25S3/c1-44(2)67-85(131)107-60-42-138-41-59-80(126)106-61-43-140-46(4)69(87(133)103-56(76(122)108-67)35-49-23-12-7-13-24-49)109-77(123)55(34-48-21-10-6-11-22-48)102-83(129)62-27-18-32-112(62)66(116)39-96-73(119)54(33-47-19-8-5-9-20-47)101-79(125)58(104-81(61)127)37-94-31-17-15-26-53(88(134)135)100-86(132)68(110-78(124)57(36-64(93)114)97-65(115)38-95-84(130)70(111-82(60)128)71(117)89(136)137)45(3)139-40-50(91)72(118)98-51(25-14-16-30-90)74(120)99-52(75(121)105-59)28-29-63(92)113/h5-13,19-24,44-46,50-62,67-71,94,117H,14-18,25-43,90-91H2,1-4H3,(H2,92,113)(H2,93,114)(H,95,130)(H,96,119)(H,97,115)(H,98,118)(H,99,120)(H,100,132)(H,101,125)(H,102,129)(H,103,133)(H,104,127)(H,105,121)(H,106,126)(H,107,131)(H,108,122)(H,109,123)(H,110,124)(H,111,128)(H,134,135)(H,136,137)/t45-,46-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59+,60-,61-,62-,67-,68+,69+,70-,71+/m0/s1
| Molecular Formula | C89H125N23O25S3 |
| Molecular Weight | 2013.2856 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 20 / 20 |
| E/Z Centers | 10 |
| Optical Activity | UNSPECIFIED |
LANCOVUTIDE, also known as duramycin, is a 19-amino-acid tetracyclic peptide antibiotic. It is in clinical development for the treatment of cystic fibrosis (CF). It activates an alternative chloride channel in lung epithelial cells by elevating intracellular calcium levels, and may potentially compensate for CF transmembrane conductance regulator deficiency in the airway epithelium and increase the volume of the airway surface liquid.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Therapeutic options for hydrating airway mucus in cystic fibrosis. | 2015 |
|
| Airway-rehydrating agents for the treatment of cystic fibrosis: past, present, and future. | 2011-01 |
|
| Effect of duramycin on chloride transport and intracellular calcium concentration in cystic fibrosis and non-cystic fibrosis epithelia. | 2010-12 |
|
| Emerging treatments in cystic fibrosis. | 2009-10-01 |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21091780
Lancovutide stimulates Cl- efflux from cystic fibrosis (CF) bronchial epithelial cells (CFBE) in a narrow concentration range (around 1 uM). However, 100 and 250 uM of lancovutide inhibits Cl⁻ efflux from CFBE cells. An inhibitor of the CF transmembrane conductance regulator, gadolinium chloride, inhibited the lancovutide-induced Cl⁻ efflux. No effect on Cl- efflux was observed in non-CF human bronchial epithelial cells (16HBE), human airway submucosal gland cell line, human pancreatic epithelial cells, CF airway submucosal gland epithelial cells, and CF pancreatic cells. The intracellular Ca2+ was increased by 3 uM lancovutide in 16HBE cells but decreased after 1, and 3 uM of lancovutide in CFBE cells.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:11:56 GMT 2025
by
admin
on
Mon Mar 31 18:11:56 GMT 2025
|
| Record UNII |
BPR0F3X56H
|
| Record Status |
FAILED
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
EU-Orphan Drug |
EU/3/02/120
Created by
admin on Mon Mar 31 18:11:56 GMT 2025 , Edited by admin on Mon Mar 31 18:11:56 GMT 2025
|
||
|
FDA ORPHAN DRUG |
107897
Created by
admin on Mon Mar 31 18:11:56 GMT 2025 , Edited by admin on Mon Mar 31 18:11:56 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL2108327
Created by
admin on Mon Mar 31 18:11:56 GMT 2025 , Edited by admin on Mon Mar 31 18:11:56 GMT 2025
|
PRIMARY | |||
|
101611009
Created by
admin on Mon Mar 31 18:11:56 GMT 2025 , Edited by admin on Mon Mar 31 18:11:56 GMT 2025
|
PRIMARY | |||
|
77834
Created by
admin on Mon Mar 31 18:11:56 GMT 2025 , Edited by admin on Mon Mar 31 18:11:56 GMT 2025
|
PRIMARY | |||
|
100000175122
Created by
admin on Mon Mar 31 18:11:56 GMT 2025 , Edited by admin on Mon Mar 31 18:11:56 GMT 2025
|
PRIMARY | |||
|
DB05029
Created by
admin on Mon Mar 31 18:11:56 GMT 2025 , Edited by admin on Mon Mar 31 18:11:56 GMT 2025
|
PRIMARY | |||
|
BPR0F3X56H
Created by
admin on Mon Mar 31 18:11:56 GMT 2025 , Edited by admin on Mon Mar 31 18:11:56 GMT 2025
|
PRIMARY | |||
|
C174642
Created by
admin on Mon Mar 31 18:11:56 GMT 2025 , Edited by admin on Mon Mar 31 18:11:56 GMT 2025
|
PRIMARY | |||
|
8995
Created by
admin on Mon Mar 31 18:11:56 GMT 2025 , Edited by admin on Mon Mar 31 18:11:56 GMT 2025
|
PRIMARY | |||
|
1391-36-2
Created by
admin on Mon Mar 31 18:11:56 GMT 2025 , Edited by admin on Mon Mar 31 18:11:56 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> ACTIVATOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|